BioCentury | Jun 26, 2020
Distillery Therapeutics

Increasing PXR activity to treat acute kidney injury

...renal mRNA levels of tubular injury, apoptosis and inflammation markers. TARGET/MARKER/PATHWAY: Pregnane X receptor (PXR); aldo-keto reductase...
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...as of Feb. 27 Target/treatment Indication Microbiome Study details Lead company or institution Abstract No. Aldo-keto reductase...
BioCentury | Feb 14, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

...HSD17B2 inhibitor that could help treat bone fractures ElexoPharm GmbH Distillery Therapeutics Renal Renal damage Aldo-keto reductase...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Renal

...genes. Next steps could include testing AKR1A1 or PKM2 inhibitors in in AKI models. TARGET/MARKER/PATHWAY: Aldo-keto reductase...
...doi:10.1038/s41586-018-0749-z CONTACT: Jonathan Stamler, Case Western Reserve University, Cleveland, Ohio email: jonathan.stamler@case.edu Chris Lieu Case Western Reserve University Aldo-keto reductase...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...oxidative phosphorylation inhibitors in AML. Juntendo University 430 Solute carrier family 25 member 39 (SLC25A39) Aldo-keto reductase...
BioCentury | Jun 9, 2017
Company News

Threshold grants OBI ex-Asian rights to TH-3424

...The candidate is a prodrug which selectively releases a DNA bis-alkylating agent upon exposure to aldo-keto reductase...
...San Francisco, Calif. OBI Pharma Inc. (TPEx:4174), Taipei, Taiwan Business: Cancer Alicia Parker TH-3424 OBI Pharma Inc. Threshold Pharmaceuticals Inc. Aldo-keto reductase...
BioCentury | Dec 30, 2016
Company News

Threshold, NIH deal

...TH-3424 (AST-106) against T cell acute lymphoblastic leukemia (ALL) xenograft cell lines, which highly express aldo-keto reductase...
...Institutes of Health , Bethesda, Md. Business: Cancer Alex Himes TH-3424 National Cancer Institute National Institutes of Health Threshold Pharmaceuticals Inc. Aldo-keto reductase...
BioCentury | Nov 18, 2016
Clinical News

Tarloxotinib: Development discontinued

...year. TH-3424 is a prodrug that selectively releases a DNA bis-alkylating agent upon exposure to aldo-keto reductase...
BioCentury | Nov 18, 2016
Clinical News

Tarloxotinib: Development discontinued

...year. TH-3424 is a prodrug that selectively releases a DNA bis-alkylating agent upon exposure to aldo-keto reductase...
BioCentury | Feb 9, 2012
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Aldo-keto reductase family 1 member...
Items per page:
1 - 10 of 12